中文
EN

EASL:乙型肝炎感染的管理临床实践指南(2025)

制定者:

2025年5月7日

109人浏览

0收藏

0次下载

摘要:

中英对照

The updated EASL Clinical Practice Guidelines on the management of hepatitis B virus (HBV) infection provide comprehensive, evidence-based recommendations for its management. Spanning ten thematic sections, the guidelines address diagnostics, treatment goals, treatment indications, therapeutic options, hepatocellular carcinoma surveillance, management of special populations, HBV reactivation prophylaxis, post-transplant care, HBV prevention strategies, and finally address open questions and future research directions. Chronic HBV remains a global health challenge, with over 250 million individuals affected and significant mortality due to cirrhosis and hepatocellular carcinoma. These guidelines emphasise the importance of early diagnosis, risk stratification based on viral and host factors, and tailored antiviral therapy. Attention is given to simplified algorithms, vaccination, and screening to support global HBV elimination targets. The guidelines also discuss emerging biomarkers and evolving definitions of functional and partial cure. Developed through literature review, expert consensus, and a Delphi process, the guidelines aim to equip healthcare providers across disciplines with practical tools to optimise HBV care and outcomes worldwide.

更新后的EASL临床实践指南为乙型肝炎病毒(HBV)感染的管理提供了全面的循证建议。该指南分为十个专题部分,涉及诊断、治疗目标、治疗适应症、治疗方案、肝细胞癌监测、特殊人群管理、HBV再激活预防、移植后护理、HBV预防策略,最后还提出了开放性问题和未来研究方向。慢性HBV仍是一项全球性的健康挑战,受影响人数超过2.5亿,肝硬化和肝细胞癌导致的死亡率很高。这些指南强调了早期诊断、基于病毒和宿主因素的风险分层以及针对性抗病毒治疗的重要性。指南还关注简化算法、疫苗接种和筛查,以支持全球消除HBV的目标。指南还讨论了新出现的生物标志物以及功能性和部分治愈的不断演变的定义。该指南是通过文献综述、专家共识和德尔菲流程制定的,旨在为各学科的医疗服务提供者提供实用工具,以优化全球的HBV治疗和结果。

下载医学界医生站


关注医生站公众号
临床指南
EASL:乙型肝炎感染的管理临床实践指南(2025)
发布时间:  2025年5月7日
制定者:  

109人浏览

0收藏

0次下载

摘要

The updated EASL Clinical Practice Guidelines on the management of hepatitis B virus (HBV) infection provide comprehensive, evidence-based recommendations for its management. Spanning ten thematic sections, the guidelines address diagnostics, treatment goals, treatment indications, therapeutic options, hepatocellular carcinoma surveillance, management of special populations, HBV reactivation prophylaxis, post-transplant care, HBV prevention strategies, and finally address open questions and future research directions. Chronic HBV remains a global health challenge, with over 250 million individuals affected and significant mortality due to cirrhosis and hepatocellular carcinoma. These guidelines emphasise the importance of early diagnosis, risk stratification based on viral and host factors, and tailored antiviral therapy. Attention is given to simplified algorithms, vaccination, and screening to support global HBV elimination targets. The guidelines also discuss emerging biomarkers and evolving definitions of functional and partial cure. Developed through literature review, expert consensus, and a Delphi process, the guidelines aim to equip healthcare providers across disciplines with practical tools to optimise HBV care and outcomes worldwide.

收藏
切换中文
阅读全文